ABBV Stock Analysis: AbbVie | NYSE
Drug Manufacturers - General | NYSE, USA | Market Cap: 500.801m USD | 12M Return: 26.8% | US00287Y1091 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 1.31B
EPS Trend: -65.2%
Qual. Beats: 0
Rev. Trend: 95.3%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
AbbVie Inc. is a research-based biopharmaceutical company that develops, manufactures, and commercializes medicines and therapies worldwide. The company operates across multiple therapeutic areas, including immunology (Skyrizi, Rinvoq), oncology (Imbruvica, Venclexta, Elahere, Epkinly, Emrelis), neuroscience (Vraylar, Duodopa, Vyalev, Botox Therapeutic), migraine (Ubrelvy, Qulipta), eye care (Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis), gastroenterology (Mavyret, Creon, Linzess/Constella), and medical aesthetics (Botox Cosmetic, Juvederm Collection). Headquartered in North Chicago, Illinois, AbbVie was incorporated in 2012.
The biopharmaceutical sector is characterized by heavy investment in research and development, long product development cycles, and reliance on patent protection for revenue generation. Major players in this space typically face significant revenue erosion when key drugs lose exclusivity, which is why diversification across therapeutic areas and a robust post-LOE pipeline (such as AbbVies Skyrizi and Rinvoq succeeding Humira) is central to the business model of large-cap pharmaceutical firms.
AbbVies portfolio spans both branded prescription pharmaceuticals and consumer-facing medical aesthetics, the latter operating on a different commercial model that targets elective procedures rather than insured medical treatment. This dual exposure to pharmaceutical and aesthetics markets is a relatively distinctive feature within large-cap biotech peers.
- Skyrizi and Rinvoq revenue offsets Humira biosimilar decline
- Botox and Juvederm aesthetics demand drives Allergan segment growth
- Pipeline catalysts in oncology and immunology support long-term outlook
| Net Income: 6.31b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.13 > 0.02 and ΔFCF/TA 0.18 > 1.0 |
| NWC/Revenue: -12.38% < 20% (prev -18.01%; Δ 5.63% < -1%) |
| CFO/TA 0.14 > 3% & CFO 19.5b > Net Income 6.31b |
| Net Debt (64.3b) to EBITDA (21.2b): 3.03 < 3 |
| Current Ratio: 0.81 > 1.5 & < 3 |
| Outstanding Shares: last quarter (1.77b) vs 12m ago -0.06% < -2% |
| Gross Margin: 71.48% > 18% (prev 70.93%; Δ 0.55% > 0.5%) |
| Asset Turnover: 47.29% > 50% (prev 42.52%; Δ 4.77% > 0%) |
| Interest Coverage Ratio: 4.57 > 6 (EBIT TTM 13.3b / Interest Expense TTM 2.92b) |
| A: -0.06 (Total Current Assets 33.7b - Total Current Liabilities 41.6b) / Total Assets 135b |
| B: -0.13 (Retained Earnings -17.3b / Total Assets 135b) |
| C: 0.10 (EBIT TTM 13.3b / Avg Total Assets 136b) |
| D: -0.04 (Book Value of Equity -5.93b / Total Liabilities 141b) |
| Altman-Z'' = -0.19 = B |
| DSRI: 0.99 (Receivables 13.8b/12.6b, Revenue 64.4b/58.3b) |
| GMI: 0.99 (GM 70.93% / 71.48%) |
| AQI: 0.95 (AQ_t 0.71 / AQ_t-1 0.75) |
| SGI: 1.10 (Revenue 64.4b / 58.3b) |
| TATA: -0.10 (NI 6.31b - CFO 19.5b) / TA 135b) |
| Beneish M = -3.01 (Cap -4..+1) = AA |
As of October 22, 2026, the stock is trading at USD 284.80 with a total of 4,391,916 shares traded. Over the past week, the price has changed by +1.08%, over one month by +8.34%, over three months by +11.89% and over the past year by +26.77%.
Current recommended Stop Loss: 276.80 (which is 2.8% or 1.2 ATR below the current price).
AbbVie has received a consensus analysts rating of 4.30. Therefore, it is recommended to buy ABBV.
- StrongBuy: 16
- Buy: 8
- Hold: 5
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 282.6 | -0.8% |
P/E Trailing = 77.4317
P/E Forward = 16.3934
P/S = 7.7781
P/B = 50.4573
P/EG = 0.5421
Revenue TTM = 64.4b USD
EBIT TTM = 13.3b USD
EBITDA TTM = 21.2b USD
Long Term Debt = 62.5b USD (from longTermDebt, last quarter)
Short Term Debt = 8.34b USD (from shortTermDebt, last quarter)
Debt = 70.8b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 64.3b USD (calculated: Debt 70.8b - CCE 6.57b)
Enterprise Value = 565b USD (501b + Debt 70.8b - CCE 6.57b)
Interest Coverage Ratio = 4.57 (Ebit TTM 13.3b / Interest Expense TTM 2.92b)
EV/FCF = 31.03x (Enterprise Value 565b / FCF TTM 18.2b)
FCF Yield = 3.22% (FCF TTM 18.2b / Enterprise Value 565b)
FCF Margin = 28.28% (FCF TTM 18.2b / Revenue TTM 64.4b)
Net Margin = 9.81% (Net Income TTM 6.31b / Revenue TTM 64.4b)
Gross Margin = 71.48% ((Revenue TTM 64.4b - Cost of Revenue TTM 18.4b) / Revenue TTM)
Gross Margin QoQ = 74.74% (prev 71.88%)
Tobins Q-Ratio = 4.18 (Enterprise Value 565b / Total Assets 135b)
Interest Expense / Debt = 4.12% (Interest Expense 2.92b / Debt 70.8b)
Taxrate = 27.39% (2.38b / 8.70b)
NOPAT = 9.67b (EBIT 13.3b * (1 - 27.39%))
Current Ratio = 0.81 (Total Current Assets 33.7b / Total Current Liabilities 41.6b)
Debt / Equity = -11.93 (negative equity) (Debt 70.8b / totalStockholderEquity, last quarter -5.93b)
Debt / EBITDA = 3.03 (Net Debt 64.3b / EBITDA 21.2b)
Debt / FCF = 3.53 (Net Debt 64.3b / FCF TTM 18.2b)
Total Stockholder Equity = -4.59b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.64% (Net Income 6.31b / Total Assets 135b)
RoE = -137.5% (negative equity) (Net Income TTM 6.31b / Total Stockholder Equity -4.59b)
RoCE = 23.00% (EBIT 13.3b / Capital Employed (Equity -4.59b + L.T.Debt 62.5b))
RoIC = 9.80% (NOPAT 9.67b / Invested Capital 98.6b)
WACC = 5.51% (E(501b)/V(572b) * Re(5.87%) + D(70.8b)/V(572b) * Rd(4.12%) * (1-Tc(0.27)))
Discount Rate = 5.87% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 17.07 | Cagr: -0.05%
[DCF] Terminal Value 75.42% ; FCFF base≈18.2b ; Y1≈18.3b ; Y5≈19.3b
[DCF] Fair Price = 133.6 (EV 300b - Net Debt 64.3b = Equity 236b / Shares 1.77b; r=8.35% [WACC [floored]]; 5y FCF grow -0.16% → 2.50% )
EPS Correlation: -65.21 | EPS CAGR: -4.22% | SUE: 0.26 | # QB: 0
Revenue Correlation: 95.26 | Revenue CAGR: 6.35% | SUE: 0.52 | # QB: 0
EPS current Quarter (2026-09-30): EPS=3.79 | Chg30d=-1.50% | Revisions=-73% | Analysts=21
EPS current Year (2026-12-31): EPS=13.96 | Chg30d=-0.34% | Revisions=-62% | GrowthEPS=+39.6% | GrowthRev=+10.6%
EPS next Year (2027-12-31): EPS=16.21 | Chg30d=-0.33% | Revisions=-25% | GrowthEPS=+16.1% | GrowthRev=+8.8%
[Analyst] Revisions Ratio: -64% (up=3, down=19)